LeMaitre Vascular (LMAT) director converts dividend rights into 10 shares, holds 5,322

Rhea-AI Filing Summary

LeMaitre Vascular director Lawrence J. Jasinski reported the release and exercise of dividend equivalent rights on 2025-12-12, converting those rights into 10 shares of common stock at $0.0000 per share in connection with vesting of 2022 restricted and performance stock unit awards. Fractional share amounts, if any, were settled in cash, leaving no remaining dividend equivalent rights. Following these transactions, he directly holds 5,322 shares of common stock.

Insider Trade Summary

Net Buyer: 10 shares

Net Buy 4 txns

Insider Jasinski Lawrence J

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	5	$0.00	$0.00
Exercise	Dividend Equivalent Rights	5	$0.00	$0.00
Exercise	Common Stock	5	$0.00	$0.00
Exercise	Common Stock	5	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 0 shares (Direct); Common Stock — 5,322 shares (Direct)

Footnotes (4)

1. F1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
2. F2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. F3. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero.
4. F4. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Shares from rights exercised: 10 shares Post-transaction holdings: 5,322 shares Exercise price: $0.0000 per share +1 more

4 metrics

Shares from rights exercised 10 shares Dividend equivalent rights released and converted on 2025-12-12

Post-transaction holdings 5,322 shares Director’s direct common stock position after reported transactions

Exercise price $0.0000 per share Dividend equivalent rights converted into common stock at no cash cost

Award grant date 12/12/2022 Restricted and performance stock unit awards linked to the rights

Key Terms

Dividend Equivalent Rights, restricted stock unit award, performance stock unit award, fractional shares

4 terms

Dividend Equivalent Rights financial

"Represents shares acquired upon release of dividend equivalent rights, as reported in Table II"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"released in connection with the vesting of a restricted stock unit award granted on 12/12/2022"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

performance stock unit award financial

"released in connection with the vesting of a performance stock unit award granted on 12/12/2022"

fractional shares financial

"Fractional shares (if any) were settled in cash on each vesting date"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

FAQ

What did LMAT director Lawrence Jasinski report in this Form 4?

Lawrence Jasinski reported the release and exercise of dividend equivalent rights, converting them into 10 shares of LeMaitre Vascular common stock on 2025-12-12. These were tied to vesting of 2022 restricted and performance stock unit awards, with fractional shares settled in cash.

How many LMAT shares does Lawrence Jasinski hold after this Form 4?

After the reported transactions, Lawrence Jasinski directly holds 5,322 shares of LeMaitre Vascular common stock. This total reflects shares received from the released dividend equivalent rights plus his prior holdings, as shown in the post-transaction ownership table.

What are dividend equivalent rights mentioned in LMAT’s Form 4?

Dividend equivalent rights in this filing are instruments economically equivalent to one share of LMAT common stock each. They were released when 2022 restricted and performance stock unit awards vested, and then converted into common shares, with any fractional amounts settled in cash.

Were the LMAT dividend equivalent rights linked to specific grant dates?

Yes. The dividend equivalent rights were released upon vesting of restricted and performance stock unit awards granted on 12/12/2022. When those awards vested on 2025-12-12, the related rights converted into LMAT common shares on a one-for-one basis.

Did Lawrence Jasinski buy or sell LMAT shares on the market in this Form 4?

The Form 4 reports exercises of dividend equivalent rights, not open-market purchases or sales. Rights tied to 2022 stock unit awards were released and converted into LMAT common shares, with no disclosed market transaction price and an exercise price of $0.0000 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/15/2025 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jasinski Lawrence J

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		5(1)	A	$0(1)	5,317	D
Common Stock	12/12/2025		M		5(1)	A	$0(1)	5,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(2)	12/12/2025		M			5(2)	(2)	(2)	Common Stock	5	$0	0(3)	D
Dividend Equivalent Rights	(4)	12/12/2025		M			5(4)	(4)	(4)	Common Stock	5	$0	0(3)	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero.

4. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.